Xebio Co., Ltd. announced consolidated and non-consolidated earnings results for the year ended March 31, 2014. For the year, on consolidated basis, the company reported net sales of JPY 204,779 million against JPY 192,628 million a year ago. Operating profit was JPY 12,295 million against JPY 12,042 million a year ago. Ordinary profit was JPY 12,985 million against JPY 12,471 million a year ago. Net profit was JPY 6,618 million against JPY 6,332 million a year ago. Cash provided by operating activities was JPY 12,385 million compared to JPY 3,092 million and capital expenditure was JPY 9,339 million compared to JPY 9,211 million for the last year.

For the year, on non-consolidated basis, the company reported net sales of JPY 142,154 million against JPY 137,991 million a year ago. Operating profit was JPY 11,028 million against JPY 10,792 million a year ago. Ordinary profit was JPY 11,893 million against JPY 11,326 million a year ago. Net profit was JPY 6,158 million against JPY 6,127 million a year ago. Capital expenditure was JPY 6,719 million compared to JPY 6,902 million for the last year.

The company provided consolidated non-consolidated and earnings guidance for the fiscal year 2015. For the year, on consolidated basis, the company expects net sales of JPY 228,727 million, operating profit of JPY 14,002 million, ordinary profit of JPY 14,312 million and net profit of JPY 7,371 million.

For the year, on consolidated basis, the company expects net sales of JPY 151,448 million, operating profit of JPY 11,638 million, ordinary profit of JPY 12,195 million and net profit of JPY 7,080 million.